Press Releases

 
Press Releases
  Date Title View
Jan 10, 2017
Q4 Revenue Increased 13% Versus Prior Year to $14.9 Million Full Year Revenue Grew 25% to $49.2 million ePlex® Global Commercialization Continued to Gain Momentum Ending 2016 with More Than 55 Customer Agreements, Representing Over 85 ePlex Instruments...
PDF
Dec 28, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California, on Wednesday, January ...
PDF
Dec 22, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has submitted 510(k) applications to the FDA for its ePlex sample-to-answer instrument and Respiratory Pathogen Panel. ...
PDF
Nov 3, 2016
Third Quarter Revenue Increased 28% Versus Prior Year to $10.8 millionePlex® Gaining Momentum in Europe; Preparation for U.S. Launch UnderwayePlex Clinical Sample Testing Completed at Clinical Study Sites; Q4 FDA Submission on TrackCompleted $29 Million ATM Offering; Ended Q3 with Cash Balance of $54.2 milli...
PDF
Nov 1, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Form ...
PDF
Oct 20, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on...
PDF
Jul 28, 2016
Second Quarter Revenue Increased 64% Versus Prior Year to $12.5 millionePlex® Systems Installed at Twelve European CustomersePlex FDA Submission Expected in Fourth Quarter CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of ...
PDF
Jul 27, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference to be ...
PDF
Jul 14, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, July 28, 2016. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on ...
PDF
Jun 8, 2016
European Customer Agreements in Place for Initial Systems CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In‐Vitro Di...
PDF
1
...
NextLast